Strata Skin Sciences, an industry leader in excimer laser therapy, presented seven illustrative cases of targeted 308-nm excimer laser phototherapy for localized and inflammatory autoimmune skin diseases at the 2026 Fall Clinical Dermatology Conference, October 8-11, 2026, in Las Vegas.
For aesthetic practices treating patients with complex skin concerns, the targeted excimer laser phototherapy findings may offer another option when topical treatments fail.
Related: Strata Skin Sciences Acquires Ra Medical
The case series examines responses across seven conditions, with follow-up data suggesting sustained results and limited adverse events.
Key findings from STRATA's 2026 Fall Clinical Dermatology Conference poster presentation – titled "Targeted 308-nkm Excimer Laser Phototherapy for Localized Inflammatory and Autoimmune Skin Diseases: An Illustrative Case Series" and authored by Suhail Hadi, MD and Mark F. Lebwohl, MD – include:
- Targeted 308-nm excimer laser phototherapy produced high levels of re-pigmentation across seven distinct conditions – including psoriasis, atopic dermatitis, palmoplantar keratoderma, vitiligo, post-inflammatory hypopigmentation, alopecia areata, and mycosis fungoides – and multiple anatomic sites, such as the scalp, hands, feet, face, neck, forearm, and thigh.
- Responses were sustained through six months to two years in the patients with follow-up data, without systemic therapy and with no adverse events beyond transient erythema.
- Excimer laser phototherapy served as an option for patients where standard topical treatments had already failed, helping those who have struggled to find relief.
"We are pleased to have the opportunity to present our findings at Fall Clinical and highlight the impact excimer laser phototherapy can have in addressing skin diseases that can be challenging to treat with topical therapies alone," said Erica Jordan, CEO, STRATA Skin Sciences.
"These cases contribute to the ongoing conversation around personalized, evidence-based approaches to inflammatory and autoimmune skin diseases, while generating the data and insights needed to help providers deliver meaningful, even life-changing outcomes for their patients."
It is important to note, however, that the release describes seven illustrative cases across seven conditions, but it does not establish efficacy across a broader patient population.
